OccuLogix, Inc.
SAN DIEGO, Feb. 25, 2010 (GLOBE NEWSWIRE) -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) announced today that a peer-reviewed article published in the current issue of Contact Lens & Anterior Eye has provided further validation of the TearLab's unique ability to accurately measure subtle changes in the condition of the ocular surface.
An abstract of the piece, entitled "Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness", can be accessed on the internet at http://alturl.com/a39q.
Quoting directly from the article, "While tear osmolarity has proven to be the most accurate method for diagnosing and following dry eye disease patients, the challenge has been to conduct the test quickly and efficiently. Until recently, the test was typically performed in a clinical laboratory setting and required large samples of tears; this was often a challenge in patients with severe dry eye. However, these difficulties diminished when in 2008 the TearLab Osmolarity System became commercially available in Europe. The system is designed to be used in an eye care practitioner's office, has great ease-of-use and requires a very small volume of tears: 50 nL."
Elias Vamvakas, the Company's Chief Executive Officer, commented, "As evidence continues to mount that tear film osmolarity is the preferred tool in the evaluation of patients suffering from DED, we are thrilled to be able to make our proprietary lab-on-a-chip technology available in most European countries as well as The United States and Canada.
Contact Lens & Anterior Eye, the official journal of the British Contact Lens Association, is a research-based journal covering all aspects of contact lens theory and practice, including original articles on invention and innovations, as well as the regular features of: Case Reports; Literary Reviews; Editorials; Instrumentation and Techniques and Dates of Professional Meetings.
About The TearLab Osmolarity System
The TearLab Osmolarity System uses a novel lab-on-a-chip approach that requires less than 50 nL (nanoliters) of tear fluid in order to measure tear Osmolarity. The TearLab Osmolarity System eliminates the challenges that previously prevented point-of-care Osmolarity testing. The TearLab System can produce a sample-to-answer result in less than 30 seconds.
About Dry Eye Disease
DED is a common condition in which the eye does not produce enough tears to keep the surface of the eye sufficiently lubricated. It affects approximately 40 million people in the US and 100 million people worldwide. In its mild to moderate forms, it can impact vision and the ability to go about daily activities. In its more severe forms, DED can lead to permanent loss of vision.
About OccuLogix, Inc. dba TearLab Corporation
OccuLogix, Inc. dba TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.